- Home
- PTGX vs TBBK Comparison
PTGX vs TBBK Comparison
Compare PTGX & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- TBBK
- Stock Information
- Founded
- PTGX 2006
- TBBK 1999
- Country
- PTGX United States
- TBBK United States
- Employees
- PTGX N/A
- TBBK N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- TBBK Major Banks
- Sector
- PTGX Health Care
- TBBK Finance
- Exchange
- PTGX Nasdaq
- TBBK Nasdaq
- Market Cap
- PTGX 4.0B
- TBBK 3.6B
- IPO Year
- PTGX 2016
- TBBK 2004
- Fundamental
- Price
- PTGX $76.75
- TBBK $77.71
- Analyst Decision
- PTGX Strong Buy
- TBBK Buy
- Analyst Count
- PTGX 9
- TBBK 4
- Target Price
- PTGX $78.11
- TBBK $68.00
- AVG Volume (30 Days)
- PTGX 1.5M
- TBBK 522.6K
- Earning Date
- PTGX 10-31-2025
- TBBK 10-30-2025
- Dividend Yield
- PTGX N/A
- TBBK N/A
- EPS Growth
- PTGX N/A
- TBBK 21.62
- EPS
- PTGX 0.80
- TBBK 4.65
- Revenue
- PTGX $209,180,000.00
- TBBK $515,889,000.00
- Revenue This Year
- PTGX N/A
- TBBK N/A
- Revenue Next Year
- PTGX $142.86
- TBBK $7.02
- P/E Ratio
- PTGX $95.33
- TBBK $16.70
- Revenue Growth
- PTGX N/A
- TBBK 11.18
- 52 Week Low
- PTGX $33.31
- TBBK $40.51
- 52 Week High
- PTGX $93.25
- TBBK $81.65
- Technical
- Relative Strength Index (RSI)
- PTGX 59.19
- TBBK 54.72
- Support Level
- PTGX $73.08
- TBBK $77.23
- Resistance Level
- PTGX $79.00
- TBBK $80.56
- Average True Range (ATR)
- PTGX 2.93
- TBBK 2.86
- MACD
- PTGX -0.37
- TBBK 0.12
- Stochastic Oscillator
- PTGX 27.14
- TBBK 63.29
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.